Therapy of the Overactive Bladder Syndrome

Overactive Bladder Clinical Trial

— TOBS  

Official title:

Comparison of Solifenacin Combined With Pelvic Floor Muscle and Whole Body Vibration Training With Solifenacin Alone in Patients With Overactive Bladder Syndrome. - A Prospective Randomized Parallel Group Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01314781
• Other study ID #: SOL-OAB-01-08
• Status: Completed
• Phase: Phase 4
• First received: January 21, 2011
• Last updated: May 19, 2016
• Start date: January 2012
• Est. completion date: March 2015

Study information

• Verified date: May 2016
• Source: Cantonal Hospital, Frauenfeld
• Contact: n/a
• Is FDA regulated: No
• Health authority: Switzerland: Swissmedic
• Study type: Interventional

Clinical Trial Summary

The aim of the present study is to investigate in patients with overactive bladder syndrome (OABS) whether a combination treatment of solifenacin with pelvic floor muscle training and whole body vibration training achieves a better treatment outcome than a treatment with solifenacin alone.

Description:

The treatment of patients with OAB in clinical practice often consists of drug therapy in combination with bladder training and/or behavioural therapies such as whole body vibration training (WBVT) and pelvic floor muscle training (PFMT). However, very little data exist on the benefits of such combinations. In particular, there are not data on the association of antimuscarinic agents with both WBVT and PFMT. In order to optimize the treatment of OAB it is of great importance to conduct studies which compare pharmacotherapy alone with a combination of pharmacotherapy and behavioural techniques.

The aim of the present study is to investigate in patients with OABS whether a combination treatment of solifenacin with pelvic floor muscle training and whole body vibration training achieves a better treatment outcome than a treatment with solifenacin alone.

At the baseline visit subjects will be randomised into 2 treatment arms. Patients randomized to group A will receive solifenacin 5mg tablet once daily and a training programme for PFMT and WBVT once a week. Subjects randomised to group B will receive solifenacin 5mg tablet once daily. Efficacy evaluation will take place at week 8 and 16. Safety evaluations will take place at each visit. At week 8, after discussion with the investigator, the patient will have an option to continue with the original dose or request a dose increase based on their satisfaction of efficacy and tolerability.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: March 2015
• Est. primary completion date: January 2014
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female patients with symptoms of overactive bladder (urinary frequency and urgency with or without incontinence) for = 3 months

• Age = 18 years old

• Urinary frequency = 8 micturitions on average per 24 hours during the 3-day micturition diary period

• At least 3 episodes of urgency with or without incontinence (= 3) during the 3-day micturition diary period

• Patient provides written informed consent

• Patient is willing to complete the micturition diary

Exclusion Criteria:

• Clinically significant bladder outflow obstruction at risk of urinary retention (at the discretion of the investigator)

• Significant post void residual volume (> 200ml)

• Uncontrolled narrow angle glaucoma, urinary or gastric retention, severe ulcerative colitis, toxic megacolon, myasthenia gravis or any other medical condition which in the opinion of the investigator makes the use of anticholinergics contraindicated

• Neurological cause of abnormal detrusor activity

• Any clinically significant condition, which in the opinion of the investigator makes the subject unsuitable for the study

• Current non-drug treatment including pelvic floor muscle and whole body vibration training

• Known contraindications for whole body vibration training (cardiovascular, neurological or orthopaedic diseases, diabetes, tumor, pacemaker)

• Pregnant women or women who intend to become pregnant during the study

• Known or suspected hypersensitivity to solifenacin or lactose

• Concomitant use of a strong cytochrome P450 3A4 inhibitor (e.g. ketoconazole)

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Drug:
• solifenacin
solifenacin 5mg tablet once daily

Procedure:
• PFMT and WBVT
pelvic floor muscle and whole body vibration training once a week

Locations

Country	Name	City	State
Switzerland	Blasenzentrum, Cantonal Hospital	Frauenfeld	Thurgau

Sponsors (2)

Lead Sponsor	Collaborator
Cantonal Hospital, Frauenfeld	Astellas Pharma Inc

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of patient perception of bladder condition (PPBC)	The primary efficacy parameter is the change from baseline in mean score of patient perception of bladder condition (PPBC). Between-treatment differences in changes from baseline to endpoint will formally be tested using an analysis of variance (ANOVA).; For the primary efficacy parameter, statistically significant superiority of solifenacin combined with pelvic floor muscle training (PFMT) and whole body vibration training (WBVT) to solifenacin alone must be obtained.	baseline and 16 weeks	No
Secondary	Change in micturitions/24h based on a 3-day micturition diary	The analysis as described for the primary endpoint will be also applied for the secondary variables: Change from baseline in mean score of number of micturitions/24h based on a 3-day micturition diary.	baseline and 16 weeks	No
Secondary	Change of urgency episodes (grade =3) /24h	The analysis as described for the primary endpoint will be also applied for the secondary variables: Change from baseline in mean number of urgency episodes (grade =3) /24h.	baseline and 16 weeks	No
Secondary	Change in volume voided per micturition	The analysis as described for the primary endpoint will be also applied for the secondary variables: Change from baseline in mean volume voided per micturition.	baseline and 16 weeks	No
Secondary	Change in number of incontinence and urge incontinence episodes/24h	The analysis as described for the primary endpoint will be also applied for the secondary variables: Change from baseline in mean number of incontinence and urge incontinence episodes/24h.	baseline and 16 weeks	No
Secondary	Change in number of pads used/24h	The analysis as described for the primary endpoint will be also applied for the secondary variables: Change from baseline in mean number of pads used/24h.	baseline and 16 weeks	No